Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharma LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 60.00p 54,177 08:00:00
Bid Price Offer Price High Price Low Price Open Price
58.00p 62.00p 60.00p 60.00p 60.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -18.72 -67.54 18.6

Faron Pharma (FARN) Latest News

More Faron Pharma News
Faron Pharma Takeover Rumours

Faron Pharma (FARN) Share Charts

1 Year Faron Pharma Chart

1 Year Faron Pharma Chart

1 Month Faron Pharma Chart

1 Month Faron Pharma Chart

Intraday Faron Pharma Chart

Intraday Faron Pharma Chart

Faron Pharma (FARN) Discussions and Chat

Faron Pharma Forums and Chat

Date Time Title Posts
14/3/201912:19Respite for ARDS sufferers1,144

Add a New Thread

Faron Pharma (FARN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-03-22 16:20:2161.041,400854.56O
2019-03-22 15:47:4960.907,8724,794.05O
2019-03-22 15:40:3358.336,6423,874.31O
2019-03-22 15:23:2860.901,642999.98O
2019-03-22 14:52:2858.608,2354,825.72O
View all Faron Pharma trades in real-time

Faron Pharma (FARN) Top Chat Posts

Faron Pharma Daily Update: Faron Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FARN. The last closing price for Faron Pharma was 60p.
Faron Pharma has a 4 week average price of 58.50p and a 12 week average price of 51p.
The 1 year high share price is 867.50p while the 1 year low share price is currently 51p.
There are currently 31,027,894 shares in issue and the average daily traded volume is 104,755 shares. The market capitalisation of Faron Pharma is £18,616,736.40.
spmc: For any one who is interested Evgen Pharma has results of 2 trials due over the next few weeks, share price is starting to rise in anticipation is up 25% already this week. Currently at 17p pre results broker target is £1.10.
craigo121: You could argue Director(non exec) buying 48k better than selling his quite considerable stash!! OVER 1 MILLION# Bet he wishes sold few months ago!! The 50k buy looks to me like a desperate attempt into showing confidence in an already depleted share price.
ic0gcds00: It hurts to see the share price plummet so much after an £8 placingThe board need to man up and come up with some positves for dhareholders
alamaison5: The cash? Just did a placing...and at a much higher price than the share price is now... Imagine the face of the investors when the price crashed. Shouldn't they average down, lol...
kirk 6: I did see that share price should be north of £8 now
craigo121: 90% drop in share price does not make a bargain! It's dropped 90% for a reason the drug failed they spent 30 million developing not much left in the coffers apart from the 2nd drug 5 million development should equate to 50-60p per share
bangers and cash1: Placebo makers, don’t know who to trust some random guy with a short or institutions who decided to buy at many multiples of the share price. Hmmm. Also how can you claim people are ramping when you are flat out lying and posting over and over again, clearly trying to scare people into selling to suit your short. Please leave.
deltalo: The bounce has happened but like a bouncing ball the heigh's get lower with each bounce. There is no income to pay for any new trials let alone pay for the rest of the last one. The whole inflation in the share price was on the back of a positive outcome from this trial from the start. What I would like to know is where's the funding coming from and if there is any new trials, how much and how many years will it take. I know something and that's I'm not waiting and I'm not paying. This will fall to its real worth.
allonblack: This is so predictable. CEO mouths off in london post period end about trial results on 8 May and then suddenly the share price week before is nothing to see here move along. Buy the dip.
paxman: Breq from over at Stocko attended. She said: Some interesting things not obvious from the presentation. Company estimates trial results by May 8. That's the date final 2017 results are announced. Obviously just a target as we all know trial results can be delayed. Mention of further share price gains possible soon. Said in a controlled but positive way. i.e. company still optimistic on trial results. 100,000 treatments available by mid 2019 because company expects demand to be that high. How could doctors not use Traumakine if effective? Breq scanned the Faron website/Linkedin etc. New appointments with a focus on delivering Traumakine so Faron still confident.
Faron Pharma share price data is direct from the London Stock Exchange
Your Recent History
Faron Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190323 09:02:57